Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

Drugs targeting dysregulated ERK1/2 signaling can cause severe cardiac side effects, precluding their wide therapeutic application. Here, a new and cardio-safe targeting strategy is presented that interferes with ERK dimerization to prevent pathological ERK1/2 signaling in the heart and cancer.

Guardado en:

Detalles Bibliográficos
Autores principales:	Angela Tomasovic, Theresa Brand, Constanze Schanbacher, Sofia Kramer, Martin W. Hümmert, Patricio Godoy, Wolfgang Schmidt-Heck, Peter Nordbeck, Jonas Ludwig, Susanne Homann, Armin Wiegering, Timur Shaykhutdinov, Christoph Kratz, Ruth Knüchel, Hans-Konrad Müller-Hermelink, Andreas Rosenwald, Norbert Frey, Jutta Eichler, Dobromir Dobrev, Ali El-Armouche, Jan G. Hengstler, Oliver J. Müller, Karsten Hinrichs, Friederike Cuello, Alma Zernecke, Kristina Lorenz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/422072e270cd48449067eb1413f577cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

Ejemplares similares